While cyclin D2 (CCND2) has previously been characterised as a BCR-ABL-dependent mediator of cell proliferation in hematopoietic cells [32], marginal changes in CCND2 (FC = 0.87, p = 0.04) expression suggest that other cyclins such as CCNA1 (FC = 12.3, p = 5.4 × 10−53) and CCNB2 (FC = 7.2, p = 9.2 × 10−55) were among the more potent regulators of cell proliferation in this cohort of CML patients. The gene discussed is PCNA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.